GSK Secures Rights to Syndivia's ADC Asset for Prostate Cancer
GSK acquires exclusive rights from Syndivia for an ADC targeting advanced prostate cancer in a deal worth up to £268 million.
The agreement reinforces GSK's oncology pipeline and gives Syndivia the scale to progress its promising asset. GlaxoSmithKline (GSK) has struck a deal to acquire exclusive rights to develop and commercialize an antibody-drug conjugate (ADC) from Syndivia targeting metastatic castration-resistant prostate cancer.
Syndivia, a France-based biotech firm specializing in next-generation ADCs, has shown this candidate delivered enhanced tumor reduction in preclinical studies while maintaining an encouraging safety profile.
GSK noted the therapy addresses a significant unmet need given the limited targeted treatment options for this advanced form of prostate cancer.
Author's summary: GSK acquires rights to Syndivia's ADC asset.